Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.37 |
| ▸ | REN | P00797 | 5/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.35 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21414397 | 0.84 | GABRG2 (0.44) | GABRG2GABRB3GABRA5SSTR4REN | |
| SCHEMBL20203531 | 0.82 | TLR9 (0.41) | GABRG2GABRB3GABRA5HSP90AA1HSP90B1 | |
| SCHEMBL23733451 | 0.80 | KEAP1 (0.40) | GABRG2GABRB3GABRA5HSP90AA1GRM5 | |
| SCHEMBL20203431 | 0.80 | KEAP1 (0.41) | GABRG2GABRB3GABRA5HSP90AA1HSP90B1 | |
| SCHEMBL20203569 | 0.78 | CDK1 (0.40) | GABRG2GABRB3GABRA5HSP90AA1HSP90B1 | |
| SCHEMBL20203529 | 0.76 | CDK1 (0.45) | HSP90AA1HSP90B1 | |
| SCHEMBL23733474 | 0.76 | CDK1 (0.45) | HSP90AA1HSP90B1 | |
| SCHEMBL23733478 | 0.75 | CDK1 (0.43) | HSP90AA1HSP90B1 | |
| SCHEMBL23733475 | 0.75 | DPP4 (0.39) | HSP90AA1HSP90B1 | |
| SCHEMBL20203568 | 0.75 | DPP4 (0.39) | HSP90AA1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| WO-2018097297-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | GABRG2 4149/4885GABRB3 4474/4885GABRA5 4019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.